Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.78 |
| ▸ | MMP13 | P45452 | 20/20 | 0.78 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP3 | P08254 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP8 | P22894 | 1/20 | 0.63 |
| ▸ | MMP12 | P39900 | 1/20 | 0.63 |
| ▸ | MMP14 | P50281 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921671 | 0.99 | MMP1 (0.78) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL3921662 | 0.97 | MMP1 (0.78) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6964194 | 0.88 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6958565 | 0.86 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6962839 | 0.86 | MMP1 (0.74) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6960491 | 0.85 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6957079 | 0.85 | MMP1 (0.80) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6960331 | 0.85 | MMP1 (0.72) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6962773 | 0.82 | MMP1 (1.00) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL6956661 | 0.82 | MMP1 (0.84) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504537-B2 | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-7504537-B2 | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20050282905-A1 | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282905-A1 | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient | MMP13, MMP3, MMP2 | MMP1 11/4885MMP13 1/4885MMP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.